| [1] |
Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas[J]. Curr Opin Oncol, 2012, 24(1):46-55.
|
| [2] |
Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: advances in diagnosis and management[J]. World J Gastroenterol, 2015, 21(32):9512-9525.
|
| [3] |
Riihimaki M, Hemminki A, Sundquist K, et al. The epidemiology of metastases in neuroendocrine tumors[J]. Int J Cancer, 2016, 139(12): 2679-2686.
|
| [4] |
Ng CS, Hobbs BP, Chandler AG, et al. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values[J]. Radiology, 2013, 269(3):758-767.
|
| [5] |
d'Assignies G, Fina P, Bruno O, et al. High sensitivity of diffusion-weighted MR imaging for the detection of liver metastases from neuroendocrine tumors: comparison with T2-weighted and dynamic gadolinium-enhanced MR imaging[J]. Radiology, 2013, 268(2):390-399.
|
| [6] |
Sundin A, Arnold R, Baudin E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological, nuclear medicine & hybrid imaging[J]. Neuroendocrinology, 2017, 105(3):212-244.
|
| [7] |
Rozenblum L, Mokrane FZ, Yeh R, et al. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: a step-by-step approach[J]. Eur J Radiol, 2020(122):108743.
|
| [8] |
Sorbye H, Baudin E, Perren A. The problem of high-grade gastroenteropancreatic neuroendocrine neoplasms: well-differentiated neuroendocrine tumors, neuroendocrine carcinomas, and beyond[J]. Endocrinol Metab Clin North Am, 2018, 47(3):683-698.
|
| [9] |
Adesoye T, Daleo MA, Loeffler AG, et al. Discordance of histologic grade between primary and metastatic neuroendocrine carcinomas[J]. Ann Surg Oncol, 2015, 22 Suppl 3:S817-821.
|
| [10] |
Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think[J]. Ann Surg, 2010, 251(2):307-310.
|
| [11] |
Yuan CH, Wang J, Xiu DR, et al. Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases[J]. Ann Surg Oncol, 2016, 23(1):244-249.
|
| [12] |
Fairweather M, Swanson R, Wang J, et al. Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database[J]. Ann Surg Oncol, 2017, 24(8):2319-2325.
|
| [13] |
Singh S, Dey C, Kennecke H, et al. Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: guidelines from a Canadian national expert group[J]. Ann Surg Oncol, 2015, 22(8):2685-2699.
|
| [14] |
Jin K, Xu J, Chen J, et al. Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: a consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)[J]. Int J Oncol, 2016, 49(5):1991-2000.
|
| [15] |
Lesurtel M, Nagorney DM, Mazzaferro V, et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? a systematic review with practice recommendations[J]. HPB, 2015. 17(1):17-22.
|
| [16] |
Partelli S, Bartsch DK, Capdevila J, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours[J]. Neuroendocrinology, 2017, 105(3):255-265.
|
| [17] |
Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases[J]. Cancer, 2015, 121(8):1172-1186.
|
| [18] |
Spolverato G, Bagante F, Aldrighetti L, et al. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: an international multi-institutional analysis[J]. J Surg Oncol, 2017, 116(3):298-306.
|
| [19] |
Zhang XF, Beal EW, Chakedis J, et al. Early recurrence of neuroendocrine liver metastasis after curative hepatectomy: risk factors, prognosis, and treatment[J]. J Gastrointest Surg, 2017, 21(11):1821-1830.
|
| [20] |
Ejaz A, Reames BN, Maithel S, et al. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis[J]. HPB, 2018, 20(3):277-284.
|
| [21] |
Frilling A, Clift AK. Surgical approaches to the management of neuroendocrine liver metastases[J]. Endocrinol Metab Clin North Am, 2018, 47(3):627-643.
|
| [22] |
Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors[J]. Surgery, 2018, 163(1):218-225.
|
| [23] |
Le Treut YP, Gregoire E, Klempnauer J, et al. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study[J]. Ann Surg, 2013, 257(5):807-815.
|
| [24] |
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?[J].J Hepatol, 2007, 47(4):460-466.
|
| [25] |
Mazzaferro V, Sposito C, Coppa J, et al. The long-term benefit of liver transplantation for hepatic metastases from neuroendocrine tumors[J]. Am J Transplant, 2016, 16(10):2892-2902.
|
| [26] |
Saxena A, Chua TC, Perera M, et al. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review[J]. Surg Oncol, 2012, 21(3):e131-141.
|
| [27] |
Zhang XF, Beal EW, Weiss M, et al. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis[J]. J Surg Oncol, 2018, 117(2):171-181.
|
| [28] |
Perysinakis I, Aggeli C, Kaltsas G, et al. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?[J]. Hormones, 2016, 15(1):15-22.
|